Clinical trials: Allogenic Bone Marrow Transplantation
Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome
Therapeutic Allogeneic Lymphocytes and Aldesleukin in Treating Patients With High-Risk or Recurrent Myeloid Leukemia After Undergoing Donor Stem Cell Transplant
This phase I/II trial is studies the side effects of giving therapeutic allogeneic lymphocytes together with aldesleukin and to see how well it works in treating patients with high-risk or recurrent myeloid leukemia after…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q)
- Trial name
- NCT00052598
- Testing
- therapeutic allogeneic lymphocytes, aldesleukin, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Fred Hutchinson Cancer Center
Graft vs Host Disease, Cutaneous Sclerosis
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation
The purpose of this research study is to better understand the onset and course of graft versus host disease (GVHD)and other immune-mediated disorders after stem cell transplant.
- Conditions
- Graft vs Host Disease, Cutaneous Sclerosis, Bronchiolitis Obliterans
- Trial name
- NCT01206309
- Where
- 14 sites in United States
- Volunteers
- 911 people
- Sponsor
- Fred Hutchinson Cancer Center
Liver Failure
Allogeneic Bone Marrow Mesenchymal Stem Cells Transplantation in Patients With Liver Failure Caused by Hepatitis B Virus (HBV)
Allogeneic Bone Marrow Mesenchymal Stem Cells Transplantation in Patients with Liver Failure Caused by hepatitis B virus (HBV)
- Trial name
- NCT01322906
- Testing
- Group 1, Group 2, Group 3
- Volunteers
- 120 people
- Sponsor
- Sun Yat-sen University
Acute Graft-Versus-Host Reaction Following Bone Marrow Transplant, Prevention of CDI in Adult Patients Being Treated With IV Beta-lactam Antibiotics
SYN-004 Safety and Tolerability in Allo-HCT Subjects
Study Objectives: 1. To evaluate the safety and tolerability of oral SYN-004 in adult allogeneic HCT (allo-HCT) recipients who develop fever after conditioning therapy and are treated with IV β-lactam antibiotics meropenem (MER)…
- Trial name
- NCT04692181
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Theriva Biologics, Inc.
Graft-versus-Host Disease
Safety and Efficacy Study of Photopheresis With UVADEX to Prevent Graft-versus-Host Disease
The purpose of this study is to determine whether Extracorporeal Photopheresis with UVADEX (ECP) prior to bone marrow or peripheral blood stem cell transplantation is effective in the prevention of Graft-versus-Host Disease…
- Trial name
- NCT00054600
- Testing
- Methoxsalen, Extracorporeal Photopheresis
- Where
- 21 sites in United States, Australia and 7 more
- Volunteers
- 60 people
- Sponsor
- Mallinckrodt
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Clinical Phase III Trial Treosulfan-based Conditioning Versus Reduced-intensity Conditioning (RIC)
This randomized allogeneic transplantation protocol compares i.v. Treosulfan-based conditioning therapy with reduced intensity i.v.
- Trial name
- NCT00822393
- Testing
- Busulfan, Treosulfan
- Where
- 33 sites in Finland, France and 4 more
- Volunteers
- 570 people
- Sponsor
- medac GmbH
Myelofibrosis
Study to Compare Busulfan-fludarabine With Thiotepa-fludarabine Regimen in Allogeneic Transplantation for Myelofibrosis
This study will be performed as a prospective multicenter phase II trial for compare busulfan-fludarabine reduced-intensity conditioning (RIC) with thiotepa-fludarabine RIC regimen prior to allogeneic transplantation of…
- Trial name
- GITMO-MF2010 (NCT01814475)
- Testing
- A: Fludarabine + Busulphan, B: Fludarabine + Thiotepa
- Where
- 21 sites in Italy
- Volunteers
- 62 people
- Sponsor
- Gruppo Italiano Trapianto di Midollo Osseo
Allogeneic Haplo-Stem Cell Transplatation (SCT), Graft Versus Host Disease
A Study to Evaluate the Effect of ATG-F on Engraftment, Graft Versus Host Disease (GVHD) and Graft Versus Leukemia (GVL) Effect in Haplo-identical SCT
This study is planned to evaluated whether ATG is needed in haploidentical stem cell transplantation
- Trial name
- NCT00616954
- Testing
- ATG-F
- Where
- Israel
- Volunteers
- 50 people
- Sponsor
- Hadassah Medical Organization
Acute Myeloid Leukemia, Acute Lymphoid Leukemia
Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
This study will evaluate the safety, tolerability, and efficacy of Orca-T, an allogeneic stem cell and T-cell immunotherapy biologic manufactured for each patient (transplant recipient) from the mobilized peripheral blood of a…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Myelodysplastic Syndromes, Acute Leukemia
- Trial name
- NCT04013685
- Testing
- Orca-T
- Where
- 21 sites in United States
- Volunteers
- 155 people
- Sponsor
- Orca Biosystems, Inc.
Leukemia, Myelodysplastic Syndrome
Phase II Trial of a Chemotherapy Alone Regimen of IV Busulfan (Busulfex), Melphalan and Fludarabine as Myeloablative Regimen Followed by an Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplant From an HLA-Identical, or HLA-Non Identical Related or Unrelated Donor
The purpose of this research study is:(1) to determine if high doses of chemotherapy without total body irradiation can allow selected stem cells to take and grow,(2) to determine if selected stem cells from the blood or marrow…
- Conditions
- Leukemia, Myelodysplastic Syndrome, Non-Hodgkin's Lymphoma, Allogeneic Marrow Transplant
- Trial name
- NCT00582933
- Testing
- BUSULFAN, MELPHALAN, FLUDARABINE, G-CSF
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS).
The purpose of the study is to determine the maximal tolerated dose and schedule of CC-486, known as oral azacitidine, in patients with AML or MDS after allogeneic hematopoetic stem cell transplant (HSCT).
- Trial name
- NCT01835587
- Testing
- CC-486
- Where
- 5 sites in United States, United Kingdom
- Volunteers
- 31 people
- Sponsor
- Celgene
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor
The primary hypothesis of this research study is that patients in remission undergoing myeloablative haploidentical hematopoietic stem cell transplantation (HSCT) on the Thomas Jefferson University (TJU) 2 Step treatment regimen…
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndromes, Biphenotypic Leukemia, Acute Lymphocytic Leukemia
- Trial name
- NCT01350245
- Testing
- Total Body Irradiation (TBI), Donor Lymphocyte Infusion (DLI), Cyclophosphamide
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
IDH2-Post-Allo-Trial for Patients with IDH2-mut Myeloid Neoplasms After Allo-SCT
This is a prospective, open label, single arm, multi-centre phase II trial aiming to evaluate the safety and efficacy of Enasidenib (investigational product) as prophylactic consolidation in patients with IDH2-mutated MDS, CMML…
- Conditions
- Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, IDH2 Gene Mutation
- Trial name
- NCT04522895
- Testing
- Enasidenib
- Where
- 11 sites in Germany
- Volunteers
- 50 people
- Sponsor
- Heinrich-Heine University, Duesseldorf
GVHD, Bone Marrow Transplant Failure
α1-antitrypsin (AAT) Levels and Functions in Allogeneic Bone Marrow Transplantation and Throughout Progression Into GVHD
Create a personalized time and context curve of patient circulating α1-antitrypsin (AAT) levels and functions before hematopoietic stem cell transplantation and throughout progression into GVHD. PRIMARY ENDPOINT 1.
- Conditions
- GVHD, Bone Marrow Transplant Failure, Alpha 1-Antitrypsin
- Trial name
- AATGVHD-MARK (NCT03188601)
- Where
- 4 sites in Israel
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Rambam Health Care Campus
Myelodysplastic Syndromes
Cohort Study Assessing the Treatment Strategy for High-Risk Myelodysplastic Syndromes in Patients Under 70
Myelodysplastic syndromes (MDS) are bone marrow malignant diseases resulting in ineffective haematopoiesis and subsequently, blood cell count decrease.
- Trial name
- COMYRE (NCT05367583)
- Testing
- Allogeneic Stem Cell Transplantation
- Where
- 10 sites in France
- Volunteers
- 107 people
- Sponsor
- University Hospital, Bordeaux
Chronic Effect of Ultraviolet Radiation on Photoaged Skin, Dermatologic Disorders
Safety Study of Bone Marrow Derived Stem Cells on Patients With Cutaneous Photoaging
The purpose of this study is to determine whether a one-time injection of allogeneic mesenchymal bone marrow cells is safe and beneficial in the treatment of photodamage on the face.
- Trial name
- NCT01771679
- Testing
- Allogeneic Mesenchymal Bone Marrow Cells
- Where
- 2 sites in United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Stemedica Cell Technologies, Inc.
CAR-T Cell Therapy, RSV Immunization
RSV Vaccine Response in Stem Cell and CAR-T Therapy Recipients
This study evaluates whether the RSV vaccine Abrysvo can produce an antibody response in patients with blood cancers who have previously received a hematopoietic stem cell transplant (HSCT) or CAR-T cell therapy.
- Conditions
- CAR-T Cell Therapy, RSV Immunization, Bone Marrow Transplant - Autologous or Allogeneic
- Trial name
- NCT07296120
- Testing
- Respiratory Syncytial Virus Prefusion F Vaccine (RSVpreF)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- The Cooper Health System
For Donors, Related Donors Giving Peripheral Blood Stem Cells (PBSC) to a Sibling
A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs
This is an open-label, multicenter, prospective pilot study of CDX-301 with or without plerixafor as a stem cell mobilizer for allogeneic transplantation (stem cells that come from another person).
- Conditions
- For Donors, Related Donors Giving Peripheral Blood Stem Cells (PBSC) to a Sibling, For Recipients, Acute Myelogenous Leukemia (AML)
- Trial name
- NCT02200380
- Testing
- CDX-301, CDX-301 and plerixafor
- Where
- 8 sites in United States
- Volunteers
- 36 people
- Sponsor
- Celldex Therapeutics
Lymphoma, B-cell Lymphoma
Optimized Donor Selection, Nonmyeloablative BMT for B-cell Lymphomas With Post-transplantation Cy and Rituximab
This phase II trial is studying how well giving fludarabine and cyclophosphamide together with total-body irradiation and rituximab works in treating patients with B-cell lymphoma or chronic lymphocytic leukemia who are…
- Conditions
- Lymphoma, B-cell Lymphoma, Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
- Trial name
- NCT00946023
- Testing
- Fludarabine, Cyclophosphamide, Total body irradiation
- Where
- United States
- Volunteers
- 135 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Allogenic Bone Marrow Transplantation
Rehab Study for alloBMT Patients
The goals of this phase III clinical trial is to determine effectiveness in the setting where it will be implemented as well as to gain an understanding of the context for implementation.
- Trial name
- CaRE-4-alloBMT (NCT07457866)
- Testing
- CaRE-4-alloBMT
- Where
- Canada
- Volunteers
- 208 people
- Sponsor
- Jennifer Jones